EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Safety profile of IL-23 inhibitors from the perspective of physicians and pharmacists: A retrospective real-world pharmacovigilance observational study based on the FAERS database

Chiwei Guo iD, Tiantian Geng, Luzhen Ye iD, Zhonghua Sun, Shujuan Zhao

Science Progress · 2026-10 · 109 (4)

DOI: 10.1177/00368504261501366 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Science Progress, online erschienen am 19.10.2026. Verfasst von Chiwei Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan Province, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Interleukin-23, Physicians, Pharmacists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China International Medical Foundation, Henan Provincial Science and Technology Research Program, Henan Medical Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Interleukin-23 (IL-23) inhibitors are widely used for psoriasis and inflammatory bowel disease, yet their long-term safety profiles require continual monitoring. This retrospective observational real-world study aimed to detect potential disproportionate reporting signals associated with tildrakizumab, risankizumab, and guselkumab using the FDA Adverse Event Reporting System (FAERS).

Methods

AE reports for tildrakizumab, risankizumab, and guselkumab from Q3 2017 to Q3 2025 were retrieved from FAERS. Disproportionality analysis using reporting odds ratios (RORs) was performed, and reported adverse events were classified by system organ classes (SOCs).

Results

A total of 1124, 8574, and 14597 AEs were retrieved for the three IL-23 inhibitors, generating 42, 286, and 348 disproportionate reporting signals, and accumulating 23, 24, and 24 SOCs. Frequently reported AEs included drug ineffectiveness, psoriasis, injection-site reactions, and infections. Disproportionate reporting signals not listed in the current FDA-approved product label comprised cardiovascular events (e.g., myocardial infarction; tildrakizumab ROR = 6.45), malignancies (e.g., malignant melanoma; risankizumab ROR = 8.57), hepatobiliary disorders, and renal complications.

Conclusion

These exploratory, hypothesis-generating disproportionate reporting signals may inform routine pharmacovigilance practice for IL-23 inhibitors, alongside well-established common reported events such as infections and systemic reactions. Further pharmacoepidemiologic studies are needed to validate these observations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedInterleukin-23PhysiciansPharmacistsHumansRetrospective StudiesPharmacovigilanceAdverse Drug Reaction Reporting SystemsAntibodies, MonoclonalUnited StatesPsoriasisDatabases, Factual

Stichwörter der Autor:innen

FAERSIL-23 inhibitorsdisproportionality analysisdisproportionate reporting signalsguselkumabrisankizumabtildrakizumab

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-23tildrakizumabrisankizumabguselkumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Pharmacy, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
  • School of Clinical Medicine, Henan University, Zhengzhou, Henan Province, China.
  • Department of Endocrinology, The First People's Hospital of Nankang District, Ganzhou, Jiangxi Province, China.
  • Department of Basic Nursing Teaching and Research Section, Jiangxi University of Technology, Nanchang, Jiangxi Province, China.
  • Department of Respiratory Medicine, the Fourth Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
  • Department of Medical, School of Nanjing University, Nanjing, Jiangshu, China.

ORCID-Profile: Chiwei Guo, Luzhen Ye

Förderung

  • China International Medical Foundation
  • Henan Provincial Science and Technology Research Program
  • Henan Medical Science and Technology Program

Zitieren

APA

Guo, C., Geng, T., Ye, L., Sun, Z., & Zhao, S. (2026). Safety profile of IL-23 inhibitors from the perspective of physicians and pharmacists: A retrospective real-world pharmacovigilance observational study based on the FAERS database. Science Progress, 109(4). https://doi.org/10.1177/00368504261501366

Vancouver

Guo C, Geng T, Ye L, Sun Z, Zhao S. Safety profile of IL-23 inhibitors from the perspective of physicians and pharmacists: A retrospective real-world pharmacovigilance observational study based on the FAERS database. Science Progress. 2026;109(4). doi:10.1177/00368504261501366

BibTeX
@article{Guo2026,
  author = {Guo, Chiwei and Geng, Tiantian and Ye, Luzhen and Sun, Zhonghua and Zhao, Shujuan},
  title = {Safety profile of IL-23 inhibitors from the perspective of physicians and pharmacists: A retrospective real-world pharmacovigilance observational study based on the FAERS database},
  journal = {Science Progress},
  year = {2026},
  volume = {109},
  number = {4},
  doi = {10.1177/00368504261501366}
}
Kostenlos starten →